Teclison is a clinical-stage biotechnology company developing innovative cancer therapeutics aimed at inducing tumor necrosis and enhancing anti-tumor immunity. Its lead product candidate, TEC-001, is a potential first-in-class agent designed to induce tumor necrosis and enhance the activity of immune checkpoint inhibitors in solid cancers with liver metastasis. The company’s therapeutic platform, Trans-Arterial TEC-001 Embolization (TATE), is being evaluated both as a monotherapy and in combination with FDA-approved immune checkpoint inhibitors. TATE and TEC-001 are in Phase 2 clinical trials for liver, colorectal, and lung cancers. Teclison is led by Founder and CEO Ray Lee, M.D., Ph.D. The company recently closed a $5.9M financing to further advance clinical studies of TEC-001.

Total raised

$6M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2022